The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

被引：0

作者：

Chowdhury, S. ^{[1
,2
]}

Abida, W. ^{[3
]}

Arranz Arija, J. ^{[4
]}

Daugaard, G. ^{[5
]}

Fizazi, K. ^{[6
]}

Gez, E. ^{[7
]}

Heidenreich, A. ^{[8
]}

Joly Lobbedez, F. ^{[9
]}

McDermott, R. ^{[10
]}

Merseburger, A. S. ^{[11
]}

Piulats Rodriguez, J. M. ^{[12
]}

Sautois, B. ^{[13
]}

Sridhar, S. ^{[14
]}

Sternberg, C. N. ^{[15
]}

Watkins, S. ^{[16
]}

Simmons, A. ^{[17
]}

Shetty, S. ^{[18
]}

Golsorkhi, A. ^{[19
]}

Ryan, C. J.

Scher, H. ^{[3
,20
]}

机构：

[1] Guys Hosp, Urol Canc, London, England

[2] Sarah Cannon Res Inst, London, England

[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA

[4] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[5] Copenhagen Univ Hosp, Rigshospitalet, Oncol, Copenhagen, Denmark

[6] Univ Paris, Grp Urogenitol, Villejuif, France

[7] Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel

[8] Univ Klinikum Koln, Klin Urol, Cologne, Germany

[9] Ctr Francois Baclesse, Med Oncol, Caen, France

[10] Tallaght & St Vincents Univ Hosp & Canc Trials Ir, Genitourinary Oncol, Dublin, Ireland

[11] Lubeck Univ Hosp, Urol Oncol, Lubeck, Germany

[12] Inst Catalan Oncol, Med Oncol, Barcelona, Spain

[13] Univ Hosp Liege, Med Oncol, Liege, Belgium

[14] Princess Margaret Hosp, Med Oncol, Toronto, ON, Canada

[15] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy

[16] Clovis Oncol Inc, Clin Sci, Boulder, CO USA

[17] Clovis Oncol Inc, Boulder, CO USA

[18] Clovis Oncol Inc, Clin Operat, Boulder, CO USA

[19] Clovis Oncol Inc, Clin Dev, Boulder, CO USA

[20] UCSF Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

836TiP

引用

页数：1

共 50 条

[41] Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
Paredero Perez, I.
Arnal, M.
Lorente, D.
Girones Sarrio, R.
Lozano Mejorada, R.
Romero Laorden, N.
Llacer Perez, C.
Castro Marcos, E.
Olmos, D.
Sanchez Hernandez, A.
ANNALS OF ONCOLOGY, 2020, 31 : S526 - S526
[42] Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
Chowdhury, S.
McDermott, R.
Piulats, J. M.
Shapiro, J. D.
Mejlholm, I.
Morris, D.
Ostler, P.
Hussain, A.
Dumbadze, I.
Goldfischer, E. R.
Pintus, E.
Benjelloun, A.
Gross, M. E.
Tejwani, S.
Chatta, G.
Font, A.
Loehr, A.
Simmons, A. D.
Watkins, S. P.
Abida, W.
ANNALS OF ONCOLOGY, 2018, 29 : 273 - 273
[43] Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
Fea, E.
Vanella, P.
Miraglio, E.
Cauchi, C.
Colantonio, I.
Denaro, N.
Di Costanzo, G.
Garrone, O.
Granetto, C.
Occelli, M.
Ricci, V.
Vandone, A. M.
Merlano, M. C.
ANNALS OF ONCOLOGY, 2016, 27
[44] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
Rexer, H.
Graefen, M.
UROLOGE, 2017, 56 (11): : 1468 - 1470
[45] Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study
Rao, Arpit
Morris, David
Assikis, Vasily J.
Jha, Gautam Gopalji
Ryan, Charles J.
Ablaza, Adriel-John
Habeck, Jenn
Loehr, Andrea
Xiao Jim
Gangolli, Esha A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[46] Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
Bryce, Alan Haruo
Piulats, Josep M.
Reaume, M. Neil
Ostler, Peter James
McDermott, Raymond S.
Gingerich, Joel Roger
Pintus, Elias
Sridhar, Srikala S.
Abida, Wassim
Daugaard, Gedske
Heidenreich, Axel
Krieger, Laurence E. M.
Sautois, Brieuc
Loehr, Andrea
Despain, Darrin
Go, Jowell
Watkins, Simon Paul
Chowdhury, Simon
Ryan, Charles J.
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[47] Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
Adashek, Jacob J.
Jain, Rohit K.
Zhang, Jingsong
CELLS, 2019, 8 (08)
[48] Phase I trial with a combination of docetaxel and 153Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC)
Eisenberger, M. A.
Lin, J.
Sinibaldi, V. J.
Carducci, M. A.
Denmeade, S.
DeWeese, T.
Song, D.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[49] TRITON 2: Drittlinientherapie beim metastasierten kastrationsrefraktären Prostatakarzinom (mCRPC)Eine internationale, multizentrische, offene Phase-2-Studie des PARP-Inhibitors Rucaparib an Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC) in Verbindung mit einer Störung der homologen Rekombination (TRITON2) – AP 99/18 der AUOTRITON 2: Third line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)An international, multicenter, open-label Phase 2 study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a homologous recombination deficiency (TRITON2) – AP 99/18 in AUO
H. Rexer
P. Hammerer
A. Merseburger
Forum, 2019, 34 (1) : 77 - 79
[50] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
Gopalakrishnan, Dharmesh
Kirk, Jason
Davis, John
George, Saby
Levine, Ellis Glenn
Beumer, Jan Hendrik
Appleman, Leonard Joseph
Tang, Dean
Chatta, Gurkamal S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →